What Logos Capital does

Logos Capital is a fundamental biotechnology-focused investment management firm founded in 2019 and headquartered in San Francisco, California, operating as Logos Global Management LP. The firm identifies and invests in transformative, first-in-class, and best-in-class biotechnology companies developing innovative therapeutics across both private and public markets, with disclosed participation in five financing rounds aggregating over $442 million between February 2025 and March 2026 spanning regenerative medicine, oral peptide therapeutics, clustering antibodies, AI-powered neurodiagnostics, and radionuclide cancer therapy. Its core differentiating technology is the proprietary Logos Analytics platform, a data science system that predicts clinical trial outcomes by modeling trial designs, replicating statistical analyses, and evaluating probability of success through advanced simulation and event tracking.

The firm is led by Managing Partners Dr. Arsani William, MD, MBA (CIO; previously drove biopharma portfolio expansion at Farallon Capital Management) and Dr. Graham Walmsley, MD, PhD (previously Principal and Portfolio Manager of the Vantage crossover fund at Versant Ventures, with involvement in BlueRock Therapeutics, Akero Therapeutics, Jecure Therapeutics, and Olema Pharmaceuticals). The broader team includes a CFO, General Counsel/CCO, VP Operations, Senior Analysts with clinical pharmacology and biomedical engineering expertise from Roche/Genentech, Amgen, Yale, and Peking University, plus an Investment Advisor who was Farallon's founding data scientist.

Logos Capital generates revenue through investment returns—management fees and performance carry—earned by deploying LP capital into transformative therapeutics. Go-to-market is sales-led and relationship-driven, targeting qualified institutional investors through direct outreach and IR channels ([email protected], phone lines at +1 (415) 801-4660 and +1 (415) 801-4670), with deal sourcing supported by the firm's proprietary analytical platform and rigorous clinical underwriting rather than external distribution.

Name

Logos Capital

Legal name

Logos Global Management LP

Website

https://logoscapital.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Logos Capital is a San Francisco-based biotechnology-focused investment fund founded in 2019 that deploys its proprietary Logos Analytics clinical-trial prediction platform to invest in transformative therapeutics across private and public markets for qualified institutional investors.

Ownership category

akta.pro rank

Product category

Biotechnology Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Biotechnology investment
• Venture capital funds
• Clinical trial analytics
• Healthcare investment management
• Biotech portfolio management

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others, Marketing or Sales

Revenue model

1. Investment Returns: Logos Capital generates returns through disciplined, data-driven investment in biotechnology companies. Their investment approach focuses on supporting transformative therapeutics capable of generating meaningful long-term returns for investors through capital appreciation and successful exit strategies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Logos Capital is a fundamental biotechnology-focused investment fund that invests capital in transformative, first-in-class, and best-in-class biotech companies across both private and public markets. The firm applies a disciplined, data-driven approach using its proprietary Logos Analytics platform to evaluate clinical trial probability of success and manage portfolio risk, providing both capital and strategic insight to portfolio companies while generating long-term returns for its investors.

Product overview

Logos Capital operates as a biotechnology investment firm offering a single core proprietary platform called Logos Analytics, which provides data-driven investment intelligence for clinical trials. The platform integrates clinical data analysis, predictive modeling, and event tracking capabilities to support investment decision-making across private and public biotechnology markets.

Differentiator

Problem solved

Functional benefit

Brands

• Logos Analytics: Proprietary data science platform designed to enhance decision-making by predicting clinical trial outcomes with precision, enabling rigorous modeling and analysis of clinical data for biotechnology investment decisions.

Products and services

• Logos Analytics Logos Analytics is Logos Capital's proprietary data science platform designed to enhance investment decision-making by predicting clinical trial outcomes. The platform enables modeling of clinical data, replicates statistical analyses, and evaluates the likelihood of trial success through advanced simulation techniques and continuous event tracking, supporting investment decisions across private and public biotechnology markets.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Baker Bros. Advisors: Long-standing biotech-focused specialist fund with both private and public investing capabilities. Comparable as a sector-focused healthcare investor targeting transformative therapeutics with concentrated, science-driven positioning.
• Cormorant Asset Management: Healthcare/biotech-focused fund investing across public equities and private financings. Direct peer in the crossover biotech-fund category with similar risk/return profile.
• Deerfield Management: Healthcare-focused investment manager leading the AdvanCell Series C in which Logos Capital participated. Comparable as a sector-specialist deploying large checks into transformative biotech.
• OrbiMed Advisors: One of the largest healthcare-dedicated investment firms globally, investing across private and public biotech. Comparable in sector focus and multi-strategy (private + public) biotech exposure.
• Perceptive Advisors: Biotech-focused crossover fund employing deep scientific diligence to invest across public and private life-sciences companies. Closely comparable investment philosophy and target portfolio companies.
• Foresite Capital: Healthcare and biotech-focused investment firm led by Jim Tananbaum. Co-led the Pinnacle Medicines Series B alongside Logos Capital; comparable in stage focus and healthcare-specialist mandate.
• Janus Henderson Investors: Large diversified asset manager with a dedicated healthcare/biotech franchise that co-invested alongside Logos Capital in Longeveron and Diagonal Therapeutics. Comparable as a public-and-private biotech capital provider.
• EcoR1 Capital: Biotech-focused fund with both private and public investing, founded by former Baker Bros. principal Oleg Nodelman. Comparable specialist mandate and similar portfolio company overlap potential.
• RA Capital Management: Healthcare-focused crossover fund investing across public and private biotech, with a similarly rigorous clinical/scientific underwriting approach. Direct competitor for biotech allocations in the same financing rounds where Logos Capital has participated (e.g., Pinnacle Medicines Series B).
• Versant Ventures: Healthcare-dedicated venture capital firm where Managing Partner Dr. Graham Walmsley previously ran the Vantage crossover fund. Comparable as a sector-focused biotech investor with crossover capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments166 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Logos Capital